Dr. Ismail Kola Leaves Schering-Plough (and Merck) — For UCB New Medicines

Per this Brussels, Belgium MarketWire.com (Europe) feed, we see the talent drain continue, as the inevitable career uncertainty festers, in the newly-combined company:

. . . .UCB New Medicines today announced the appointment of Ismail Kola, Executive Vice President, UCB & President of UCB New Medicines^TM, UCB’s discovery research through to ‘proof of concept’ organization. Ismail Kola will join UCB’s Executive Committee with effect from November 23, 2009. . . .

Since March 2007, Dr. Kola has occupied the role of Senior Vice-President, Discovery Research and Early Clinical Research & Experimental Medicine, and Chief Scientific Officer at Schering-Plough. He came to Schering Plough from Merck where in January 2003 he was appointed Senior Vice President/Site Head, Basic Research. Prior to that, Ismail was Vice President, Research, and Global Head, Genomics Science and Biotechnology with Pharmacia Corporation, and served as a consultant to SmithKline Beecham Pharmaceuticals where he was also a member of the Genomics Advisory Board. . . .